Aptamers-based drug: A new paradigm for precise treatment.
3/5 보강
TL;DR
This review focuses on the latest progress in the ApDCs field from 2023 to 2025, with an emphasis on discussing solutions and emerging strategies to overcome the aforementioned challenges, aiming to provide references for promoting the further development and clinical application of ApDCs.
OpenAlex 토픽 ·
HER2/EGFR in Cancer Research
Protein Degradation and Inhibitors
Advanced Breast Cancer Therapies
This review focuses on the latest progress in the ApDCs field from 2023 to 2025, with an emphasis on discussing solutions and emerging strategies to overcome the aforementioned challenges, aiming to p
APA
Yuwen Zhou, Shiqin Hong, et al. (2026). Aptamers-based drug: A new paradigm for precise treatment.. European journal of medicinal chemistry, 307, 118683. https://doi.org/10.1016/j.ejmech.2026.118683
MLA
Yuwen Zhou, et al.. "Aptamers-based drug: A new paradigm for precise treatment.." European journal of medicinal chemistry, vol. 307, 2026, pp. 118683.
PMID
41698301 ↗
Abstract 한글 요약
Aptamer-drug conjugates (ApDCs) represent innovative therapeutics in recent drug development, emerging as a new modality for precision delivery. As a novel targeted cancer therapy strategy, ApDCs have significant advantages over antibody-drug conjugates (ADCs), including smaller molecular weight, higher chemical stability, lower immunogenicity, stronger tissue penetration, and easier engineering. Currently, ApDCs have established themselves as a highly competitive research landscape, garnering considerable attention from scientists worldwide. This review focuses on the latest progress in the ApDCs field from 2023 to 2025, with an emphasis on discussing solutions and emerging strategies to overcome the aforementioned challenges, aiming to provide references for promoting the further development and clinical application of ApDCs.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Characterization and Risk Factors of Folliculitis after Hair Transplantation: A Multicenter Retrospective Study.
- Botulinum Toxins for the Treatment of Raynaud Phenomenon: A Systematic Review With Meta-analysis.
- Reversing Cuproptosis Tolerance with Twinborn Metallic Polymer Nanoparticles for Enhancing Efficacy of Chemo-Immunotherapy.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Correction: Piperlongumine Inhibits Lung Cancer Growth by Inducing Endoplasmic Reticulum Stress Leading To Suppression of M2 Macrophage Polarization.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.